Cargando…

Public procurement of antineoplastic agents used for treating breast cancer in Brazil between 2013 and 2019

BACKGROUND: Breast cancer is the most common cancer among women in Brazil and the country’s public health care system is the main care provider. Timely treatment can increase the chance of cure, prevent metastasis and improve quality of life. Effective public procurement of antineoplastic agents can...

Descripción completa

Detalles Bibliográficos
Autores principales: dos Santos, Ranailla Lima Bandeira, Pepe, Vera Lúcia Edais, Osorio-de-Castro, Claudia Garcia Serpa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284867/
https://www.ncbi.nlm.nih.gov/pubmed/35840933
http://dx.doi.org/10.1186/s12885-022-09851-3
_version_ 1784747658503520256
author dos Santos, Ranailla Lima Bandeira
Pepe, Vera Lúcia Edais
Osorio-de-Castro, Claudia Garcia Serpa
author_facet dos Santos, Ranailla Lima Bandeira
Pepe, Vera Lúcia Edais
Osorio-de-Castro, Claudia Garcia Serpa
author_sort dos Santos, Ranailla Lima Bandeira
collection PubMed
description BACKGROUND: Breast cancer is the most common cancer among women in Brazil and the country’s public health care system is the main care provider. Timely treatment can increase the chance of cure, prevent metastasis and improve quality of life. Effective public procurement of antineoplastic agents can therefore improve access to drug therapy. This study investigates patterns in the procurement of selected antineoplastic agents used for treating breast cancer by public bodies and avoidable expenditure on these drugs between January 2013 and December 2019. METHODS: We selected antineoplastic agents used for adjuvant or preoperative chemotherapy listed in the 2018 Breast Cancer Diagnosis and Treatment Guidelines and included in category L of the WHO Anatomical Therapeutic Chemical classification system. We analyzed regular purchases of antineoplastic agents registered in the Integrated General Services Administration System (SIASG), considering purchased quantity, unit price, date of purchase and procuring entity. Prices were inflation-adjusted to July 2019 based on the National Consumer Price Index. RESULTS: A total of 10 antineoplastic agents were selected. Trastuzumab and tamoxifen accounted for the largest share of total spending and largest volume of purchases, respectively. The Ministry of Education was the largest purchaser in volume terms of all the drugs studied, except trastuzumab 440 mg, where the category “Other Institutions” accounted for most purchases, and vinorelbine 20 mg, where the Ministry of Health made most purchases. The category “Other Institutions” accounted for the largest share of total spending. Total avoidable expenditure was R$99,130,645. Prices paid for medicines and avoidable expenditure were highest in the Ministry of Defense. CONCLUSIONS: The differences observed in the performance of different categories of buyers as to amounts purchased and prices practiced for antineoplastic agents could be reduced by employing strategies to expand the centralization of purchases, resulting in expanded access to breast cancer medicines in the public sector.
format Online
Article
Text
id pubmed-9284867
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92848672022-07-16 Public procurement of antineoplastic agents used for treating breast cancer in Brazil between 2013 and 2019 dos Santos, Ranailla Lima Bandeira Pepe, Vera Lúcia Edais Osorio-de-Castro, Claudia Garcia Serpa BMC Cancer Research BACKGROUND: Breast cancer is the most common cancer among women in Brazil and the country’s public health care system is the main care provider. Timely treatment can increase the chance of cure, prevent metastasis and improve quality of life. Effective public procurement of antineoplastic agents can therefore improve access to drug therapy. This study investigates patterns in the procurement of selected antineoplastic agents used for treating breast cancer by public bodies and avoidable expenditure on these drugs between January 2013 and December 2019. METHODS: We selected antineoplastic agents used for adjuvant or preoperative chemotherapy listed in the 2018 Breast Cancer Diagnosis and Treatment Guidelines and included in category L of the WHO Anatomical Therapeutic Chemical classification system. We analyzed regular purchases of antineoplastic agents registered in the Integrated General Services Administration System (SIASG), considering purchased quantity, unit price, date of purchase and procuring entity. Prices were inflation-adjusted to July 2019 based on the National Consumer Price Index. RESULTS: A total of 10 antineoplastic agents were selected. Trastuzumab and tamoxifen accounted for the largest share of total spending and largest volume of purchases, respectively. The Ministry of Education was the largest purchaser in volume terms of all the drugs studied, except trastuzumab 440 mg, where the category “Other Institutions” accounted for most purchases, and vinorelbine 20 mg, where the Ministry of Health made most purchases. The category “Other Institutions” accounted for the largest share of total spending. Total avoidable expenditure was R$99,130,645. Prices paid for medicines and avoidable expenditure were highest in the Ministry of Defense. CONCLUSIONS: The differences observed in the performance of different categories of buyers as to amounts purchased and prices practiced for antineoplastic agents could be reduced by employing strategies to expand the centralization of purchases, resulting in expanded access to breast cancer medicines in the public sector. BioMed Central 2022-07-15 /pmc/articles/PMC9284867/ /pubmed/35840933 http://dx.doi.org/10.1186/s12885-022-09851-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
dos Santos, Ranailla Lima Bandeira
Pepe, Vera Lúcia Edais
Osorio-de-Castro, Claudia Garcia Serpa
Public procurement of antineoplastic agents used for treating breast cancer in Brazil between 2013 and 2019
title Public procurement of antineoplastic agents used for treating breast cancer in Brazil between 2013 and 2019
title_full Public procurement of antineoplastic agents used for treating breast cancer in Brazil between 2013 and 2019
title_fullStr Public procurement of antineoplastic agents used for treating breast cancer in Brazil between 2013 and 2019
title_full_unstemmed Public procurement of antineoplastic agents used for treating breast cancer in Brazil between 2013 and 2019
title_short Public procurement of antineoplastic agents used for treating breast cancer in Brazil between 2013 and 2019
title_sort public procurement of antineoplastic agents used for treating breast cancer in brazil between 2013 and 2019
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284867/
https://www.ncbi.nlm.nih.gov/pubmed/35840933
http://dx.doi.org/10.1186/s12885-022-09851-3
work_keys_str_mv AT dossantosranaillalimabandeira publicprocurementofantineoplasticagentsusedfortreatingbreastcancerinbrazilbetween2013and2019
AT pepeveraluciaedais publicprocurementofantineoplasticagentsusedfortreatingbreastcancerinbrazilbetween2013and2019
AT osoriodecastroclaudiagarciaserpa publicprocurementofantineoplasticagentsusedfortreatingbreastcancerinbrazilbetween2013and2019